China’s Homegrown Anti-Cancer Drug Wins International Recognition
Sintilimab shown to have favourable activity and acceptable toxicity in Chinese patients with relapsed or refractory classical Hodgkin lymphoma. China's homegrown drug Sintilimab designed for...